37 CFR 1.821 - Nucleotide and/or amino acid sequence disclosures in patent applications
| Cite as | 37 CFR 1.821 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
44 practice notes
-
Patent cases: Patent business goals; implementation,
...resulting from that one application. Clearly, something needs to be done to address this onslaught of paper. The current regulations at 37 CFR 1.821(e) indicate that the electronic version of the sequence listing is a ``copy'' of the paper sequence listing, and that the paper sequence listi......
-
Legal Framework for Electronic Filing System - Web (EFS-Web)
...for EFS-Web filings does not apply to national stage submissions. See MPEP Sec. 1893.01(c). Any sequence listing in compliance with 37 CFR 1.821(c) or (e), and any computer program listing in compliance with 37 CFR 1.96, submitted via EFS-Web will be excluded when determining the applicatio......
-
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.
...(No. 95-728). A protein molecule can only be claimed as the complete and specific sequence of amino acids comprising the protein. See 37 C.F.R. § 1.821 (2000). The particular amino acids that comprise a protein chain are frequently interchangeable with other amino acids without changing the......
-
Transmittal Letter to the U.S. Designated/Elected Office (DO/EO/US) Concerning a Submission under 35 U.S.C. 371 (for PCT filing dates on or after March 16, 2013)-PTO-1390
...of attorney and/or change of address letter. 14. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.3 and 37 CFR 1.821-1.825 (not required if sequence listing in text format was indicated on the PCT Request as part of the International Application and the seq......
Request a trial to view additional results
4 cases
-
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.
...(No. 95-728). A protein molecule can only be claimed as the complete and specific sequence of amino acids comprising the protein. See 37 C.F.R. § 1.821 (2000). The particular amino acids that comprise a protein chain are frequently interchangeable with other amino acids without changing the......
-
Ex parte Sims, Appeal 1999-1430
...by the examiner in the rejection of the claims under appeal." [3] We note as does the examiner (Answer, page 3) that the requirements of 37 CFR §§ 1.821-1.825 represent petitionable rather than appealable subject matter. Accordingly, the Board of Patent Appeals and Interferences has no juri......
-
Ex parte Raghupathi, Appeal 2001-1025
...applications that contain a disclosure of an unbranched sequence of four or more amino acids must comply with the requirements of 37 C.F.R. §§ 1.821-1.825. We note that an unbranched sequence of six amino acid is set forth on page 4 of appellants' specification. However, it does not appear ......
-
Ex parte Pike, Appeal 2020-002657
...Appeal Br. 3. [2] The Examiner also entered an objection to the Specification for failure to comply with the sequence requirements of 37 C.F.R. §§ 1.821-1.825, and Appellant traverses that objection on appeal. See Final Act. 2 (entered February 14, 2019); Appeal Br. 5. We will not review th......
7 firm's commentaries
-
USPTO Extends Missing Parts Pilot Program for Another Year
...fee required under 37 CFR 1.16(s); (7) any English translation required by 37 CFR 1.52(d); and (8) a sequence listing in compliance with 37 CFR 1.821–1.825 (if applicable). Applicants must satisfy any compact disc requirements and provide an English translation of any provisional applicatio......
-
USPTO Provide Guidance On Patent Examination Policies And Procedures, Revise Manual Of Patent Examining Procedure
...to reissue applications. MPEP 1410 now states that reissue applications containing sequence listing must comply with the sequence rules in 37 CFR 1.821-1.825 upon MPEP 1415.01(I) has been revised to the maintenance fee updates forth in Setting and Adjusting Patent Fees During Fiscal Year 20......
-
USPTO Seeks Comments on New Sequence Listing Standard
...became effective in 1998. U.S. Patent Rules concerning application disclosures of certain nucleotide and amino acid sequences (i.e., 37 C.F.R. §§ 1.821 - 1.825) are consistent with WIPO In October 2010, the Committee on WIPO Standards (CWS) established a Task Force, led by the European Pate......
-
USPTO To Accelerate Examination Of Cancer-Related Immunotherapy Treatment Methods
...not have been granted any other special status (e.g. PPH, prioritized examination). comply with the sequence requirements set forth in 37 C.F.R. §§ 1.821 through 1.825. not be subject to a nonpublication request. Petitions must be submitted with a request for early publication. Petition Tim......
Request a trial to view additional results